In Russia, trials have begun for a meningococcal vaccine against five virus strains.

Feb. 22, 2023

The Russian pharmaceutical company "Pharm Aid" has announced the start of clinical trials for a next-generation meningococcal vaccine that protects against five virus strains.

According to RIA Novosti, citing the company, the studies will be conducted in stages with the participation of volunteers of all ages, including children aged 9-12 months. The drug is administered intramuscularly.

It is specified that the vaccine protects against the most common meningococci in the world, belonging to serogroups A, C, W, Y, and X.

Andrey Pozdnyakov, an infectious disease doctor and chief physician of the clinical diagnostic laboratory LLC "Invitro-Siberia," previously commented on the news about the creation of a vaccine against the dangerous RSV (respiratory syncytial virus) infection in Russia. 

Source

The company has established a pharmacovigilance system in accordance with Russian and international requirements.

If you become aware of an adverse reaction associated with the use of our product, please report it to us by any convenient means.

  • Fill out the feedback form on our website
  • By calling the toll-free hotline +7 (800) 350-80-24
  • By email pv@pharmaid.com

By entering your contact details and clicking the 'send' button, you confirm your consent to the processing of your personal data, in accordance with Federal Law No. 152-FZ of July 27, 2006 'On Personal Data,' under the conditions and for the purposes specified in the Consent for Personal Data Processing.